Security
Kura Oncology, Inc. Common Stock · KURA
KURANASDAQCommon stockCurrentCIK 1422143Updated Oct 3, 2026
Name history
ZETA ACQUISITION CORP III · through Mar 10, 2015
KURA price & chart
Loading TradingView…
NASDAQ:KURA on TradingView ↗About the company
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.
In the news
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
Other Events
Items 8.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
144 filing
4 filing
SCHEDULE 13G/A - filed by MONTANOVA CAPITAL, LLC regarding Kura Oncology, Inc.
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 738,363,000Source | 760,159,000Source | 448,935,000Source | 456,306,000Source |
| Property, Plant and Equipment, NetUSD | 7,855,000Source | 1,682,000Source | 1,859,000Source | 2,540,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 149,099,000Source | 224,462,000Source | 37,318,000Source | 51,802,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 8,804,000Source | — | — | — |
| Inventory, NetUSD | 413,000Source | — | — | — |
| Assets, CurrentUSD | 708,663,000Source | 744,829,000Source | 432,481,000Source | 446,426,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 32,206,000Source | 17,434,000Source | 8,524,000Source | 8,441,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,302,000Source | 5,803,000Source | 6,993,000Source | 3,842,000Source |
| Other Assets, NoncurrentUSD | 14,543,000Source | 7,845,000Source | 7,602,000Source | 3,288,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 564,228,000Source | 346,519,000Source | 51,662,000Source | 36,028,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 9,000Source | 8,000Source | 7,000Source | 7,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,174,088,000Source | -895,422,000Source | -721,439,000Source | -568,808,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,024,000Source | 764,000Source | -1,271,000Source | -8,032,000Source |
| Stockholders' Equity Attributable to ParentUSD | 174,135,000Source | 413,640,000Source | 397,273,000Source | 420,278,000Source |
| Additional Paid in Capital, Common StockUSD | 1,347,190,000Source | 1,308,290,000Source | 1,119,976,000Source | 997,111,000Source |
| Liabilities and EquityUSD | 738,363,000Source | 760,159,000Source | 448,935,000Source | 456,306,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 116,974,000Source | 78,712,000Source | 35,263,000Source | 24,057,000Source |
| Operating Lease, Liability, CurrentUSD | 1,277,000Source | 1,881,000Source | 1,506,000Source | 2,318,000Source |
| Accounts Payable, CurrentUSD | 5,017,000Source | 1,469,000Source | 2,300,000Source | 1,533,000Source |
| Operating Lease, Liability, NoncurrentUSD | 9,469,000Source | 5,190,000Source | 6,362,000Source | 2,548,000Source |
| Other Liabilities, NoncurrentUSD | 3,165,000Source | 1,795,000Source | 705,000Source | 265,000Source |
| Additional Financial Items | ||||
| Long-term Debt, Current MaturitiesUSD | 0Source | 2,607,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 9,711,000Source | 6,916,000Source | 9,332,000Source | 9,158,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 37,108,000Source | 33,897,000Source | 28,082,000Source | 26,318,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 6,744,000Source | — | — | — |
| Increase (Decrease) in InventoriesUSD | 413,000Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | 4,499,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -64,058,000Source | 134,317,000Source | -124,824,000Source | -110,062,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -13,098,000Source | -101,590,000Source | 15,557,000Source | 32,627,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 6,638,000Source | 472,000Source | 168,000Source | 626,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,793,000Source | 154,417,000Source | 94,783,000Source | 38,565,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -75,363,000Source | 187,144,000Source | -14,484,000Source | -38,870,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 149,099,000Source | 224,462,000Source | 37,318,000Source | 52,012,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 998,000Source | 1,096,000Source | 1,064,000Source | 73,000Source |
| Income Taxes Paid, NetUSD | 2,308,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 37,108,000Source | — | — | — |
| Amortization of Debt Issuance CostsUSD | 515,000Source | 523,000Source | 477,000Source | — |
| DepreciationUSD | 1,032,000Source | 848,000Source | 849,000Source | 759,000Source |
| General and Administrative ExpenseUSD | — | 77,111,000Source | 50,569,000Source | 47,053,000Source |
| Income Tax Expense (Benefit)USD | 297,000Source | 2,018,000Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 1,512,000Source | 1,619,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -278,666,000Source | -173,983,000Source | -152,631,000Source | -135,840,000Source |
| Nonoperating Income (Expense)USD | 25,262,000Source | 21,230,000Source | 13,173,000Source | 4,025,000Source |
| Operating ExpensesUSD | 371,113,000Source | 247,078,000Source | 165,804,000Source | 139,865,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 2,000,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 24,721,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | 10,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 67,482,000Source | 53,883,000Source | — | — |
| Selling, General and Administrative ExpenseUSD | 119,982,000Source | — | — | — |
| Operating Income (Loss)USD | -303,631,000Source | -193,195,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -278,369,000Source | -171,965,000Source | — | — |
| Income Tax Expense (Benefit)USD | 297,000Source | 2,018,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -278,666,000Source | -173,983,000Source | -152,631,000Source | -135,840,000Source |
| Earnings Per Share, BasicUSD per share | -3.18Source | -2.02Source | -2.08Source | -2.03Source |
| Earnings Per Share, DilutedUSD per share | -3.18Source | -2.02Source | -2.08Source | -2.03Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 87,676,000Source | 86,161,000Source | 73,229,000Source | 66,990,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 87,676,000Source | 86,161,000Source | 73,229,000Source | 66,990,000Source |
| Interest Expense (non-operating)USD | 1,512,000Source | 1,619,000Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | — | 77,111,000Source | 50,569,000Source | 47,053,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -278,369,000Source | — | — | — |
| Interest and Other IncomeUSD | 26,774,000Source | 22,849,000Source | 14,722,000Source | 4,254,000Source |
| Interest ExpenseUSD | — | — | 1,549,000Source | 229,000Source |
| Nonoperating Income (Expense)USD | 25,262,000Source | 21,230,000Source | 13,173,000Source | 4,025,000Source |
| Operating ExpensesUSD | 371,113,000Source | 247,078,000Source | 165,804,000Source | 139,865,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 2,000,000Source |
| Research and Development ExpenseUSD | 251,074,000Source | 169,967,000Source | 115,235,000Source | 92,812,000Source |
Filing attachments
kura-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 kura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kura Oncology Reports SECOND Quarter 2026 Financial Results - KOMZIFTI®(ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q - - KOMZIFTI® achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class, establishing leadership after just two full quarters of launch - - Long-term, frontline AML data presented at EHA 2026 support pote…
Read attachment ↗kura-ex99_1.htm · 8-K · 2026-06-04
EX-99.1 2 kura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan Amended and Restated by the Board: March 6, 2015 Approved by the Stockholders: March 6, 2015 Amended by the Board: September 26, 2022 and April 4, 2023 Approved by the Stockholders: May 31, 2023 Amended by the Board: April 7, 2024 Approved by the Stockholders: June 5, 2024 Amended by the Board: April 8, 2025 Approved by the Stockholders: June 5, 2025 Amended …
Read attachment ↗kura-ex99_2.htm · 8-K · 2026-06-04
EX-99.2 3 kura-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 Kura Oncology, Inc. Amended and Restated 2015 Employee Stock Purchase Plan ADOPTED BY THE BOARD OF DIRECTORS: MARCH 6, 2015 APPROVED BY THE STOCKHOLDERS: MARCH 6, 2015 Amended by the Board of Directors: April 9, 2026 Approved by the Stockholders: June 4, 2026 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to pu…
Read attachment ↗kura-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 kura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kura Oncology Reports FIRST Quarter 2026 Financial Results - $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization - - Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum - - Broad and rapid payer access achieved, with > 93% coverage and favorable positioning across > 12 million lives - - Multiple…
Read attachment ↗kura-ex99_1.htm · 8-K · 2026-03-05
EX-99.1 2 kura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kura Oncology Reports Fourth Quarter and full year 2025 Financial Results - KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions - - Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients - - Orange Book listing of patents extending up to 2044 reinforces long-term value for KO…
Read attachment ↗d18498dex991.htm · 8-K · 2026-01-29
EX-99.1 2 d18498dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 AMENDED AND RESTATED BYLAWS OF KURA ONCOLOGY, INC. (A DELAWARE CORPORATION) A MENDED AND R ESTATED E FFECTIVE AS OF J ANUARY 28, 2026 ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware and the name of the corporation’s registered agent at such address shall be as set forth in the certificate of incorporation of the corporation (as the same may be amended and/or rest…
Read attachment ↗